2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole
A review of taints and odors in the pharmaceutical and consumer healthcare industries.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 56-62

Lessons from the food and beverage industries

TBA and TCA taints are long and well recognized in the food, wine, and beverage industries (2). The technical literature from these industries is useful to the pharmaceutical industry regarding the origin of these odors and taints, analytical methods developed, and risk-management strategies that may be employed.


Table II: Representative literature references to Organohalogen taints in the food, beverage, consumer healthcare, and pharmaceutical industries (1966 to 2010).
It is widely recognized that TBA and TCA taints can migrate into packaging materials, ingredients, and products by leaching or diffusion. Literature examples from the food and beverage industries indicate that chemically porous polymeric materials, such as wood, corrugate, and plastic, are susceptible to contamination with these taints (see Table II). Likewise, food and beverage products are quite porous and can readily absorb these taints from contaminated materials. Consumers having sensory expectations are more likely to notice contamination of food, beer, and wine because these taints can also produce unpleasant tastes that would more likely be noted during consumption.

PDA TBA/TCA benchmarking survey

The PDA task force prepared a survey to benchmark knowledge of TBA/TCA odors and taints and actions taken within the bio/pharmaceutical industry to mitigate the risks of these musty/moldy odors and taints. PDA distributed the survey in May 2011 to 27 pharmaceutical, consumer healthcare, and biotechnology manufacturers, as well as packaging suppliers represented on the Task Force, to collect definitive feedback (3). The survey was sent to specific experts within these companies, and it was requested that the responses reflect the current position of the organization regarding how issues with these taints are handled.

The responses from 19 companies (70% of those polled) were used to help benchmark industry practice and conduct a gap analysis. The 32-question survey covered the following areas: complaint-handling system, analytical methods, supply-chain controls, and regulatory issues. The full results from this survey are available through PDA (3).

Vulnerabilities in the supply chain


Figure 1: Halophenol to haloanisole biomethylation conversions (adapted from Ref. 2). (FIGURE COURTESY OF AUTHORS)
One outcome of the PDA Technical Report is that each company should review its supply chain to ensure that proper good distribution practices (GDPs) and controls are implemented to mitigate the risk associated with TBP, TCP, TBA, and TCA contamination. To date, the primary focus in industry has been on the use of heat-treated (HT) wood pallets that are certified to be TBP/TCP-free to prevent risks of TBA/TCA odors and taints from entering into the supply chain. Other potential sources through which TBP/TCP can enter the supply chain should also be considered and are addressed in the PDA TBA Technical Report. For example, TBP/TCP can come from recycled materials and disinfectants. In addition, because fungi perform the biomethylation of TBP (or TCP) to TBA (or TCA), ventilation and moisture controls should be implemented to minimize fungal growth on pallets.

The primary root cause for TBA-tainted product recalls in the bio/pharmaceutical industry was that wood treated with TBP (or TCP) was used to construct pallets that were then used to ship and or store plastic packaging components. In this supply chain, the TBP (or TCP) from the pallets was biomethylated to TBA (or TCA) which then contaminated plastic packaging components before product filling and, ultimately, the drug products stored in these components. The ability of TBP/TCP and the more volatile TBA/TCA, formed by biomethylation, to readily migrate from one material to another also makes the taint distribution uneven. It also makes determining the ultimate root cause of the contamination challenging.

According to the International Plant Protection Convention (IPPC), most pallets shipped across national borders must be made of materials that are free of invasive insects and plant diseases. The standards for these pallets are specified in the International Standards for Phytosanitary Measures (ISPM) No. 15. Regulation of Wood Packaging Material in International Trade (2009 Revision). In accordance with ISPM 15, wood pallets intended for international trade should be constructed of either heat-dried or methyl bromide-treated lumber. Therefore, tainting could be associated with imported TBP/TCP-treated wood or treated wood pallets from outside the US.

There are approximately 1–2 billion wood pallets in circulation in the US, and an estimated 500 million pallets are replaced annually. Total control of TBP-impregnated wood pallets entering into US commerce, therefore, may be difficult, if not impossible. A unique challenge may be the control of wood pallets constructed from TBP-treated lumber entering Puerto Rico from neighboring South America, where TBP is registered for use as a wood preservative. It is known that TBP is used as a wood preservative in other regions of the world, including Northern Asia and Eastern Europe. In addition, multiple examples in the literature from the food and beverage industries highlight that TBA tainting has been an issue in other regions of the world, including Australia. Based on the available literature, goods are more susceptible to TBA tainting if exposed to TBP-treated wood when moving from higher to lower temperatures under high humidity because the risk of condensation increases. Higher moisture levels increase the risk for fungal growth and, ultimately, for biomethylation of TBP (TCP) to TBA (TCA). The PDA Technical Report provides more details about these specific risks.

The report addresses controls that can be employed to mitigate the possibility of TBA/TCA formation and tainting for pallets, shipping containers, corrugate, and plastics. The main approaches include:

  • Eliminate use of TBP/TCP in the supply chain
  • Minimize risk of fungal growth in the supply chain
  • Use appropriate humidity control and ventilation in warehouses
  • Monitor wood materials, such as pallets, shipping containers and corrugate, for mold growth
  • Train personnel to be on alert for musty, moldy odor characteristics of TBA/TCA.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here